Skip to content

Study · Animal study (in vivo) · chicken · 1989

5 results

Influence of thymic hormone on cell-mediated and humoral immune responses in Marek's disease.

Quere P, Dambrine G, Bach MA

Veterinary microbiology1 Jan 1989Cited by 5 (Europe PMC)

PMID2538023 (opens in a new tab)DOI10.1016/0378-1135(89)90090-4 (opens in a new tab)PepBankPUB-02538023
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In MDV-infected chickens, daily thymulin treatment did not modify the time course of Marek's disease.

    In plain wordsIn infected chickens, thymulin did not change the course of Marek's disease.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeMarek's disease time course
    Study

    chickenn: not reported in source

    Marek's disease virus infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous injectionAs given in this study (chicken).

    Source sentences

    Summary
    In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In MDV-infected chickens, daily thymulin treatment did not prevent macroscopic tumor development.

    In plain wordsIn infected chickens, thymulin did not prevent visible tumors.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeMacroscopic tumors
    Study

    chickenn: not reported in source

    Marek's disease virus infection
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · subcutaneous injectionAs given in this study (chicken).

    Source sentences

    Summary
    In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In MDV-infected chickens, thymulin did not affect neutralizing antiviral antibody levels.

    In plain wordsIn infected chickens, thymulin did not change virus-neutralizing antibody levels.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeNeutralizing antiviral antibodies
    Study

    chickenn: not reported in source

    Marek's disease virus infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous injectionAs given in this study (chicken).

    Source sentences

    Summary
    No effect was noted on the levels of neutralizing anti-viral antibodies.
    1 context sentence
    Summary · context
    In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In MDV-infected chickens, thymulin suppressed cellular immunity measured by splenic cytotoxicity against MD-specific lymphoblastoid cells 4-6 weeks after inoculation.

    In plain wordsIn infected chickens, thymulin reduced immune activity measured against Marek's disease-specific target cells.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseCytotoxicity against MD-specific target cells
    Study

    chickenn: not reported in source

    Marek's disease virus infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous injectionAs given in this study (chicken).

    Source sentences

    Summary
    Nevertheless, thymulin treatment resulted in significant suppression of the cellular immune response 4-6 weeks post-inoculation, monitored by splenic cytotoxicity against MD-specific and natural killer-sensitive lymphoblastoid cell lines.
    1 context sentence
    Summary · context
    In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In MDV-infected chickens, thymulin suppressed cellular immunity measured by splenic cytotoxicity against natural killer-sensitive cells 4-6 weeks after inoculation.

    In plain wordsIn infected chickens, thymulin reduced immune activity measured against natural killer-sensitive target cells.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseCytotoxicity against natural killer-sensitive target cells
    Study

    chickenn: not reported in source

    Marek's disease virus infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneous injectionAs given in this study (chicken).

    Source sentences

    Summary
    Nevertheless, thymulin treatment resulted in significant suppression of the cellular immune response 4-6 weeks post-inoculation, monitored by splenic cytotoxicity against MD-specific and natural killer-sensitive lymphoblastoid cell lines.
    1 context sentence
    Summary · context
    In very sensitive histocompatible (B13/B13) chickens inoculated with the HPRS-16 strain of MDV at 10 days of age, treatment with synthetic thymulin by daily subcutaneous injection failed to modify the time course of Marek's disease (MD) and did not prevent the development of macroscopic tumors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.